AR Isolate Bank – Year 1 – Customer Satisfaction Survey for CDC AR Isolate Bank Form Approved
OMB Control No.: 0920-1071
Exp. Date: 06/30/2018
REQUEST TO CUSTOMER—FIRST WAVE:
FROM: [email protected]
TO: POCs from order list
SUBJECT: 10-min survey about AR Isolate Bank
Dear AR Isolate Bank customer,
The FDA-CDC AR Isolate Bank launched in July 2015 and, as we approach our one-year mark, we would like to hear feedback on how it has provided value to your organization and how it can be improved.
Take the 10-minute survey here: [LINK]
The survey will be open until [DATE].
With your permission, we will contact you based on your responses to develop success stories that will be published on our website and in other CDC and FDA materials.
On behalf of FDA and CDC, we appreciate your participation in this survey. Your feedback will help us build a repository of isolates that are the most useful in the fight against antimicrobial resistance.
Best,
Jean B. Patel, PhD, D(ABMM)
Acting Director, Office of Antimicrobial Resistance
Centers for Disease Control and Prevention
Ribhi
M. Shawar, Ph.D, D(ABMM)
Branch
Chief
General
Bacteriology and Antimicrobial Susceptibility Branch
CDRH/OIR
Division of Microbiology Devices
Food
and Drug Administration
[email protected]
REQUEST TO CUSTOMER—SECOND WAVE:
FROM: [email protected]
TO: POCs from order list
SUBJECT: How is the AR Isolate Bank doing?
Dear AR Isolate Bank customer,
This is a reminder that the FDA-CDC AR Isolate Bank satisfaction survey will be closing [DATE].
Please take 10 minutes to complete the survey and provide feedback on how it has provided value to your organization and how it can be improved.
Take the survey now: [LINK]
With your permission, we will contact you based on your responses to develop success stories that will be published on our website and in other CDC and FDA materials.
On behalf of FDA and CDC, we appreciate your participation in this survey. Your feedback will help us build a repository of isolates that are the most useful in the fight against antimicrobial resistance.
Best,
Jean B. Patel, PhD, D(ABMM)
Acting Director, Office of Antimicrobial Resistance
Centers for Disease Control and Prevention
Ribhi
M. Shawar, Ph.D, D(ABMM)
Branch
Chief
General
Bacteriology and Antimicrobial Susceptibility Branch
CDRH/OIR
Division of Microbiology Devices
Food
and Drug Administration
[email protected]
SURVEY HOSTED ON:
SurveyMonkey.com
INTRODUCTION:
Thank
you for providing feedback on the FDA-CDC AR Isolate Bank.
The
purpose of the survey is to capture how the AR Isolate Bank has
provided value to customers and how it can be improved.
The
information gathered from this survey will not be published and will
only inform next steps of implementation.
PROPOSED QUESTIONS:
How did you first hear about the AR Isolate Bank? [can select only one]
FDA website
CDC website
FDA talk or presentation
CDC talk or presentation
Colleague
Other: [open-ended]
What AR Isolate Bank panels did you/your organization order? Check all that apply.
How has your organization used the panels from the AR Isolate Bank? Check all that apply.
To develop (research, challenge, accelerate) a diagnostic device, test, or assay
To satisfy a specific request and/or support an application to FDA
To validate a diagnostic test for implementation in my laboratory
To develop (research, challenge, accelerate) an antibiotic
Other: [open-ended]
Based on your answer to Question #4, please provide more detail about how you have used the panels from the AR Isolate Bank. Please do not provide proprietary information. General descriptions for how the isolates helped improve process, increase product accuracy, meet organization priorities, add value, or support other AR strategies are appreciated. If you have not yet used the isolates, please explain how you intend to use them in the future. [open-ended]
Please take a moment to think about the AR Isolate Bank panels you received. Rate satisfaction with the following during your experience. [Likert scale: Very dissatisfied, Dissatisfied, Neither Dissatisfied nor Satisfied, Satisfied, Very satisfied, Not applicable]
Diversity of panels
Descriptions of panel organisms
Viability of organisms
Confirmatory testing in your lab corresponded to isolate description
Responsiveness of staff to problems with panels or isolates
Please comment on ratings given above about satisfaction with panels. [open-ended]
CDC and FDA are working together to expand the AR Isolate Bank collection. What additional isolate panels or information would be valuable to you/your organization in the future? How can the current collection be improved? [open-ended]
Please take a moment to think about the AR Isolate Bank ordering process. Rate satisfaction with the following during your experience. [Likert scale: Very dissatisfied, Dissatisfied, Neutral, Satisfied, Very satisfied, Not applicable]
Order instructions provided on the website
Duration of entire process (from initial order to delivery)
Responsiveness of staff
Information provided with the isolates (i.e., MIC results and interpretation, sequencing information)
Please comment on ratings given above about satisfaction with panels. [open-ended]
CDC and FDA are working to improve the AR Isolate Bank website. What other information in content or structure would you like to see added or improved? How can the current website be improved? [open-ended]
Which option below best describes your organization? [can select only one]
Academic
Commercial diagnostic company
Commercial laboratory
Federal agency
Hospital or clinic
Pharmaceutical company
Public health laboratory
Other: [open-ended]
Can we contact you for additional information? To improve the AR Isolate Bank overall and develop success stories, we would like to contact some customers for more information about their experience. We will NOT publish responses provided in this survey or confidential, proprietary information. [can select only one]
If yes, please provide your name and email address. [open-ended]
Public
reporting burden of this collection of information is estimated to
average 10 minutes per response, including the time for reviewing
instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing the
collection of information. An agency may not conduct or sponsor,
and a person is not required to respond to a collection of
information unless it displays a currently valid OMB Control Number.
Send comments regarding this burden estimate or any other aspect of
this collection of information, including suggestions for reducing
this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton
Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-1071
| File Type | application/msword |
| Author | Katy Capers |
| Last Modified By | Samuel, Lee (CDC/OID/NCEZID) |
| File Modified | 2016-05-26 |
| File Created | 2016-05-20 |